ArticleThe Lancet regional health. Southeast Asia2026
Toxicity during induction of pulsed versus continuous prednisolone in children with acute lymphoblastic leukaemia: a multi-centre, open label, randomised, phase 3 trial from India (2016-2022).
Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Background: Despite the use of similar treatment protocols, induction treatment-related mortality (TRM) in children with ALL in India is 5%, compared to <1% in high income countries. This study evaluated pulsed prednisolone during induction to reduce toxicity. Methods: ICiCLe-ALL-14 (CTRI/2015/12/006434), an open-label, randomised, multicentre trial. Children ≤ 10-years with newly diagnosed B-cell precursor ALL, risk-stratified to standard- or intermediate-risk, were randomised (1:1) to receive prednisolone 60 mg/m Findings: Of 3315 patients screened at 6 centres, 2505 were eligible and 1246 randomised (623 per group). Thirty (2.4%) patients died during induction: 22/623 (3.5%) and 8/623 (1.3%) in R1A and R1B respectively (absolute risk difference 2.3%, 95% CI 0.54-4.1; p = 0.0149). Relative risk of induction death was 2.75 (95% CI 1.2-6.1) for R1A versus R1B. Grade 3-5 toxicities occurred in 46.4% (289/623) and 45.4% (283/623) of patients (p = 0.7762). CR rates were 98.8% (581/588) and 98.0% (594/606); MRD ≥ 0.01% at EoI was 26.2% and 27.9%; 3-year EFS 72.7% (95% CI 68.2-76.7) and 72.2% (67.6-76.3); OS 85.0% (81.5-87.8) and 87.0% (83.6-89.3) in R1A and R1B respectively. Multivariable analysis confirmed higher risk of induction death with continuous prednisolone (HR 3.06, 95% CI 1.4-6.9, p = 0.0069) and anthracycline use (HR 5.44, 95% CI 1.6-18.9 p = 0.0077). Interpretation: Pulsed prednisolone (R1B) during induction significantly reduced treatment-related deaths, particularly early deaths from infections compared to continuous dosing (R1A), without compromising CR rates, MRD clearance, EFS, or OS. Anthracycline use was an independent risk factor for induction mortality. Higher white cell count and anthracycline use independently predicted grade 3-4 toxicity. Funding: This study was funded partly by the Indian Council of Medical Research (Reference 79/159/2015/NCD-III), the National Cancer Grid (Reference 2016/001), DBT-Wellcome India Alliance (Margdarshi IA/M/12/1/500261) and a centre grant from the Tata Consultancy Services Foundation to the trial centre.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.